Satellos Bioscience(NASDAQ) MSLE

Current Price$9.52

Market Cap$177.59M

Since IPO (2021)-61%

5 Year-54%

1 Year+62%

1 Month+49%

Satellos Bioscience last closing stock price
Metric	Price	Date
Last close	USD 8.53	2026-07-21

Satellos Bioscience stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-5.33%	USD 9.01	2026-07-14
1 month	+49.3%	USD 5.71	2026-06-18
3 month	+14.43%	USD 7.45	2026-04-22
Year to date	+44.98%	USD 5.88	2025-12-31
1 year	+62.46%	USD 5.25	2025-07-21
3 year	+77.6%	USD 4.80	2023-07-19
5 year	-54.46%	USD 18.72	2021-03-22
Since inception	-60.93%	USD 21.82	2021-08-18

Satellos Bioscience Financials at a Glance

Market Cap

$177.59M

Revenue (TTM)

$0.00

Net Income (TTM)

-$28.50M

EPS (TTM)

-$1.81

P/E Ratio

-4.70

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.52

Volume

113,291

Open

$8.37

Price

$9.52

Volume

113,291

Open

$8.37

Previous Close

$9.78

Daily Range

$8.37 - $9.85

52-Week Range

$4.64 - $13.39

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.52

Volume

113,291

Open

$8.37

Previous Close

$9.78

Daily Range

$8.37 - $9.85

52-Week Range

$4.64 - $13.39

Estimated Earnings Date

Aug 12, 2026

MSLE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Satellos Bioscience

Satellos Bioscience Inc. is a biotechnology company focused on developing innovative medicines for degenerative muscle diseases. The company operates primarily in Canada and Australia, utilizing its proprietary MyoReGenX platform to create advanced treatment options.

Products and Services

Development of SAT-3247, an oral drug candidate for Duchenne muscular dystrophy
Proprietary MyoReGenX platform for muscle stem cell research
Collaborative research agreements with leading institutions

Growth Outlook

Strong pipeline with potential for significant market impact in muscle diseases
Partnerships with Ottawa Hospital Research Institute and University of British Columbia
Increasing demand for innovative treatments in the biotechnology sector

Financial Highlights

Recent quarterly net income of -$9.77 million, reflecting ongoing R&D investments
Cash and short-term investments totaling $70.14 million as of March 31, 2026
Current ratio of 11.13, indicating strong liquidity position

Satellos Bioscience Inc. is positioned in a growing sector with a focus on addressing unmet medical needs. The company's innovative approach and strategic partnerships enhance its potential for future growth. Recent financial data indicates a solid liquidity position, which may support ongoing research and development efforts. The biotechnology industry continues to evolve, and Satellos is well-placed to capitalize on emerging opportunities in the treatment of muscle diseases.

AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Frank Gleeson, MBA

Website

www.satellos.com

Headquarters

Toronto, ON M5J 2J1, CA

MSLE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-51.42%

Return on Capital

-95.23%

Return on Assets

-25.56%

Earnings Yield

-21.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$177.59M

Shares Outstanding

20.83M

Volume

113.29K

Avg. Volume

55.35K

Financials (TTM)

Gross Profit

-$5.00K

Operating Income

-$30.02M

EBITDA

-$30.02M

Operating Cash Flow

-$25.68M

Capital Expenditure

-$9.94K

Free Cash Flow

-$25.69M

Cash & ST Invst.

$70.14M

Total Debt

$0.00

Satellos Bioscience Performance Analysis

Satellos Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Satellos Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Satellos Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.93	-52.5%
2023	2023-12-31	USD -1.64	-44.1%
2024	2024-12-31	USD -2.14	31.2%
2025	2025-12-31	USD -1.70	-20.5%

Satellos Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	25.0%
Q3	2025-09-30	N/A
Q4	2025-12-31	-33.3%
Q1	2026-03-31	-10.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$986.00

+1.0%

Gross Margin

0.00%

N/A

Market Cap

$177.59M

N/A

Market Cap/Employee

$9.87M

N/A

Employees

N/A

Net Income

-$9.77M

-59.1%

EBITDA

-$10.04M

-55.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$70.14M

+70.3%

Total Debt

$0.00

N/A

Accounts Receivable

$728.39K

+115.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-25.56%

N/A

Return on Invested Capital

-20.67%

N/A

Free Cash Flow

-$9.46M

-28.4%

Operating Cash Flow

-$9.45M

-28.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,510.84+0.00%

^DJIDJI

^DJIDJI$52,306.84+0.00%

^IXICNASDAQ

^IXICNASDAQ$25,750.82-0.00%

BTCBitcoin

BTCBitcoin$65,855.00-0.01%

SPCXSPCX

SPCXSPCX$117.74-0.05%

AAPLAAPL

AAPLAAPL$323.95-0.01%

AMZNAMZN

AMZNAMZN$243.10-0.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$23.04+0.04%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.79-0.03%

PATHUiPath

PATHUiPath$10.70-0.11%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$115.26-0.07%

NOKNokia

NOKNokia$10.28-0.03%

FFord Motor Company

FFord Motor Company$14.42+0.01%

TET1 Energy Inc.

TET1 Energy Inc.$6.03-0.01%

Questions About MSLE

What is the current price of Satellos Bioscience?

Satellos Bioscience is trading at $9.78 per share.

What is the 52-week range for Satellos Bioscience?

Over the past 52 weeks, Satellos Bioscience has traded between $4.64 and $13.39.

How much debt does Satellos Bioscience have?

As of the most recent reporting period, Satellos Bioscience reported total debt of $0.00.

How much cash does Satellos Bioscience have on hand?

Satellos Bioscience reported $18.70M in cash and cash equivalents in its most recent financial results.

What is Satellos Bioscience’s dividend yield?

Satellos Bioscience does not currently have a dividend yield.

Satellos Bioscience(NASDAQ) MSLE

Satellos Bioscience Financials at a Glance

MSLE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Satellos Bioscience

MSLE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Satellos Bioscience Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MSLE

What is the current price of Satellos Bioscience?

What is the 52-week range for Satellos Bioscience?

How much debt does Satellos Bioscience have?

How much cash does Satellos Bioscience have on hand?

What is Satellos Bioscience’s dividend yield?

Premium Investing Services